Ironwood Pharmaceuticals (NASDAQ:IRWD) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen downgraded shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from a buy rating to a hold rating in a research report report published on Saturday morning.

A number of other research firms also recently weighed in on IRWD. Citizens Jmp lifted their target price on Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the stock a “market outperform” rating in a report on Thursday, February 26th. Weiss Ratings reissued a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, April 27th. Zacks Research downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $3.70 price target on shares of Ironwood Pharmaceuticals in a research report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Ironwood Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $6.23.

Ironwood Pharmaceuticals Stock Performance

IRWD opened at $4.22 on Friday. Ironwood Pharmaceuticals has a fifty-two week low of $0.53 and a fifty-two week high of $5.78. The company has a market capitalization of $688.11 million, a P/E ratio of 7.03 and a beta of 0.29. The stock has a fifty day moving average of $3.70 and a 200-day moving average of $3.63.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its earnings results on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 37.48% and a net margin of 28.26%.The firm had revenue of $106.51 million for the quarter, compared to analyst estimates of $92.11 million. On average, equities research analysts predict that Ironwood Pharmaceuticals will post 0.88 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Alexander J. Denner sold 6,730,800 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $3.05, for a total value of $20,528,940.00. Following the completion of the transaction, the director owned 9,188,635 shares of the company’s stock, valued at $28,025,336.75. The trade was a 42.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 12.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IRWD. Integrated Wealth Concepts LLC raised its stake in Ironwood Pharmaceuticals by 21.4% in the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,406 shares in the last quarter. LSV Asset Management acquired a new position in Ironwood Pharmaceuticals in the fourth quarter valued at about $30,000. Captrust Financial Advisors acquired a new position in Ironwood Pharmaceuticals in the second quarter valued at about $32,000. Jump Financial LLC acquired a new position in Ironwood Pharmaceuticals in the fourth quarter valued at about $34,000. Finally, DGS Capital Management LLC acquired a new position in Ironwood Pharmaceuticals in the fourth quarter valued at about $35,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.